Treatment of mesenchymal stromal cells (MSCs) isolated from lung cancer patients led to a significant reduction in the production of IL-6 and chemokines like CCL2, and CCL3 that play key roles in tumour progression and immune modulation [221]. Here, CCL2 is linked to neoplasm.